[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001254556A1 - Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate - Google Patents

Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate

Info

Publication number
AU2001254556A1
AU2001254556A1 AU2001254556A AU5455601A AU2001254556A1 AU 2001254556 A1 AU2001254556 A1 AU 2001254556A1 AU 2001254556 A AU2001254556 A AU 2001254556A AU 5455601 A AU5455601 A AU 5455601A AU 2001254556 A1 AU2001254556 A1 AU 2001254556A1
Authority
AU
Australia
Prior art keywords
ascorbate
ferrous ion
treatment
diseases
compositions useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254556A
Inventor
V. G. Sunetra Ekanayake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3835537 CANADA Inc
Original Assignee
Ocean Nutrition Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocean Nutrition Canada Ltd filed Critical Ocean Nutrition Canada Ltd
Publication of AU2001254556A1 publication Critical patent/AU2001254556A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Removal Of Specific Substances (AREA)

Abstract

Compositions comprising ferrous ion and an ascorbate have a synergistic effect on cartilage development. Therapeutic compositions comprising ferrous ion and an ascorbate are therefore useful in the treatment of osteoarthritis. The addition of a glucosamine, such as glucosamine hydrochloride, to the composition has a further enhanced effect on cartilage production. Therapeutic compositions comprising ferrous ion, an ascorbate and a glucosamine derivative are even more useful in the treatment of osteoarthritis.</PTEXT>
AU2001254556A 2000-04-28 2001-04-25 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate Abandoned AU2001254556A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20036100P 2000-04-28 2000-04-28
US60/200,361 2000-04-28
PCT/CA2001/000564 WO2001082938A2 (en) 2000-04-28 2001-04-25 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate

Publications (1)

Publication Number Publication Date
AU2001254556A1 true AU2001254556A1 (en) 2001-11-12

Family

ID=22741396

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254556A Abandoned AU2001254556A1 (en) 2000-04-28 2001-04-25 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate

Country Status (8)

Country Link
US (1) US6632804B2 (en)
EP (1) EP1276485B1 (en)
JP (1) JP2003531858A (en)
AT (1) ATE334690T1 (en)
AU (1) AU2001254556A1 (en)
CA (1) CA2343439C (en)
DE (1) DE60121932D1 (en)
WO (1) WO2001082938A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851458B2 (en) * 1999-06-22 2010-12-14 Joint Juice, Inc. Cartilage enhancing food supplements and methods of preparing the same
ES2190379B1 (en) * 2001-12-21 2004-11-16 Bioiberica,S.A GLUCOSAMINE SALT PREPARATION PROCEDURE.
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US20040086581A1 (en) * 2002-11-06 2004-05-06 Jones Edwin B. Bio-energetic joint and arthritis pain formula
CN1232256C (en) * 2003-03-27 2005-12-21 中国人民解放军第三军医大学 Application of N-acetylglucosamine in The preparation of medicine for treating local injure or whole body syndrome due to self immune reaction
US8633246B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) * 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
ES2255829B1 (en) * 2004-08-06 2007-08-16 Bioiberica, S.A. NEW USE OF GLUCOSAMINE SALTS.
AU2005330856B2 (en) * 2005-04-13 2011-05-19 Megmilk Snow Brand Co., Ltd. Nutrient composition
DE102005020327A1 (en) 2005-04-30 2006-11-09 Multibind Biotec Gmbh Decontamination solutions and their use for denaturation, modification, degradation, solubilization and removal of proteins, nucleic acid molecules and microorganisms from surfaces
DE102006001213A1 (en) * 2006-01-10 2007-07-12 Multibind Biotec Gmbh Synergistic solution of ascorbic acid or its derivatives and metal ions efficient, selective killing of pathological mammalian cells
WO2007143660A1 (en) * 2006-06-05 2007-12-13 Stokely-Van Camp, Inc. Reducing muscle soreness with glucosamine compositions
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
BE1019135A5 (en) * 2010-01-08 2012-03-06 Lab Smeets Nv FOOD SUPPLEMENT CONTAINING GLUCOSAMINE.
AU2014225619A1 (en) * 2013-03-06 2015-10-15 Rutgers, The State University Of New Jersey Nutritional supplement/feed formula and methods of use thereof to reduce development of Osteochondrosis Dissecans (OCD) lesions
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel
JP2019501221A (en) * 2015-12-30 2019-01-17 アレクサンドル・ヴィレノヴィチ・アサフォフＡＳＡＦＯＶ， Ａｌｅｘａｎｄｅｒ Ｖｉｌｅｎｏｖｉｃｈ Formulations, manufacturing methods and uses for the treatment of extracellular matrix components of peripheral joints, spinal joints and / or connective tissues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2822317A (en) * 1955-12-12 1958-02-04 Smith Kline French Lab Aqueous iron-ascorbic acid preparation
IT1044707B (en) 1968-10-26 1980-04-21 Rotta Research Lab PROCEDURE FOR THE PREPARATION OF GLUCOSANINE SALTS AND PHARMACEUTICAL PREPARATIONS INCLUDING THESE GLUCOSAMINE SALTS AS ACTIVE AGENTS
NZ194947A (en) 1979-09-18 1983-06-14 C Holland Composition containing calcium and ferrous ions for treatment of rheumatoid arthritis
WO1985000033A1 (en) * 1983-06-18 1985-01-03 Japan As Represented By Director-General Of Agency Chemically active aqueous solution and solid substance containing ferrous ion
US5405613A (en) * 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
US5364845C1 (en) 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
AT408416B (en) 1996-07-19 2001-11-26 Norbert Fuchs PHARMACEUTICAL OR DIETETIC COMPOSITIONS
GB2317109B (en) 1996-08-28 2000-06-21 Farmsense A therapeutic composition for the treatment and repair of connective tissue in mammals
GB9621273D0 (en) 1996-10-11 1996-11-27 Cortecs Ltd Therapeutic method
US6245360B1 (en) * 1998-06-26 2001-06-12 John S. Markowitz Nutritional supplement
US6177476B1 (en) * 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
DE20004010U1 (en) * 2000-03-02 2000-06-21 Febena Pharma GmbH, 50825 Köln Dietary composition containing glycosaminoglycans

Also Published As

Publication number Publication date
CA2343439C (en) 2003-06-24
DE60121932D1 (en) 2006-09-14
US6632804B2 (en) 2003-10-14
JP2003531858A (en) 2003-10-28
CA2343439A1 (en) 2001-07-09
EP1276485B1 (en) 2006-08-02
EP1276485A2 (en) 2003-01-22
WO2001082938A2 (en) 2001-11-08
WO2001082938A3 (en) 2002-08-08
ATE334690T1 (en) 2006-08-15
US20010044425A1 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU2001254556A1 (en) Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate
IL164509A0 (en) Furyl compounds
PT1420801E (en) Use of fucans in the treatment of adhesions, arthritis and psoriasis
MXPA04004452A (en) Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis.
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
IL164613A0 (en) Thienyl compounds
MXPA05012901A (en) Clear, stable topical compositions of clarithromycin and processes for their preparation.
IL172364A (en) Factor vii or viia gla domain variants
MX2008000838A (en) Compositions and methods for treating gram positive bacterial infection in a mammalian subject.
IL172773A0 (en) Formulations for the treatment of arhritis conditions
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE0203070D0 (en) Novel compounds
SI1638582T1 (en) Use of hyaluronic acid for preparing compositions for treating recurrent oral cavity aphthas
AU2566101A (en) Compounds and methods for the treatment of pain
WO2003101398A8 (en) Variants of antithrombin iii
IL166596A0 (en) Salt of morphine-6-glucoronide
DE60005548D1 (en) COMPOSITION CONTAINING AN EXTRACT OF PERNA CANALICULUS, METHYLSULFONYLMETHANE AND GLUCOSAMINE AND USE
WO2005030148A3 (en) Tetrahydroindolone derivatives for treatment of neurological conditions
AU2001276437A1 (en) Use of polysulphated cyclodextrins for treating osteoarthritis
CA2314817A1 (en) Synergistic agents for enhancing tissue repair
MXPA05003633A (en) 2&#34; oxo-voruscharin and derivatives thereof.
WO2001025264A3 (en) Substituted phosphinate based peptide derivatives
AU2003298203A1 (en) Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles
BRPI0414454A (en) antibacterial agents
WO2004018481A3 (en) Gossypol derivatives, production methods thereof and uses of same